Inhibitors of HIV-1 entry and integration: Recent developments and impact on treatment

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 7, Issue 2, 2013, Pages 151-161

  Sharma, Anil K ^a   George, Varghese ^b   Valiathan, Ranjini ^b   Pilakka Kanthikeel, Sudheesh ^c   Pallikkuth, Suresh ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Art; Entry inhibitors; HIV; HIV patents; HIV treatment; HIV 1; Integrase inhibitors; Raltegravir

Indexed keywords

1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; ABACAVIR PLUS LAMIVUDINE; APLAVIROC; CD4 ANTIGEN; CENICRIVIROC; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; COBICISTAT; DARUNAVIR; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; IBALIZUMAB; INTEGRASE INHIBITOR; MARAVIROC; PLACEBO; PLERIXAFOR; RALTEGRAVIR; RITONAVIR; SIFUVIRTIDE; TIPRANAVIR; UNINDEXED DRUG; VICRIVIROC;

ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STEM CELL MOBILIZATION; SYSTEMIC DISEASE; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT; VIRAL TROPISM; VIREMIA; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS LOAD;

ANIMALS; ANTI-HIV AGENTS; DRUG DESIGN; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; VIRUS INTERNALIZATION;

EID: 84878656477     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872213X11307020006     Document Type: Review

References (129)

1. Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol 2000; 74 (4):1961-1972.
2. Weiss CD, Levy JA, White JM. Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J Virol 1990;64 (11):5674-5677.
3. Daar ES, Li XL, Moudgil T, Ho DD. High concentrations of re-combinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA 1990; 87 (17):6574-6578.
4. Davey RT, Jr., Boenning CM, Herpin BR, Batts DH, Metcalf JA, Wathen L, et al. Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J Infect Dis 1994; 170 (5):1180-1188.
5. Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, et al. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med 1990; 112 (4):247-253.
6. Turner S, Tizard R, DeMarinis J, Pepinsky RB, Zullo J, Schooley R, et al. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120. Proc Natl Acad Sci USA 1992; 89 (4):1335-1339.
7. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995;11 (5):533-539.
8. Guo Q, Ho HT, Dicker I, Fan L, Zhou N, Friborg J, et al. Bio-chemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol 2003; 77 (19):10528-10536.
9. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 2003; 100 (19):11013-11018.
10. Hanna GJ, Lalezari J, Hellinger JA, Wohl DA, Nettles R, Persson A, et al. Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects. Antimicrob Agents Chemother 2011; 55 (2):722-728.
11. Nowicka-Sans B, Gong YF, McAuliffe B, Dicker I, Ho HT, Zhou N, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother 2012; 56 (7):3498-3507.
12. Nettles RE, Schurmann D, Zhu L, Stonier M, Huang SP, Chang I, et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis 2012; 206 (7):1002-1011.
13. Burkly LC, Olson D, Shapiro R, Winkler G, Rosa JJ, Thomas DW, et al. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol 1992; 149 (5):1779-1787.
14. Boon L, Holland B, Gordon W, Liu P, Shiau F, Shanahan W, et al. Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: Preclinical assessment in non-human primates. Toxicology 2002; 172 (3):191-203.
15. Burkly L, Mulrey N, Blumenthal R, Dimitrov DS. Synergistic inhibition of human immunodeficiency virus type 1 envelope gly-coprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies. J Virol 1995; 69 (7):4267-4273.
16. Reimann KA, Lin W, Bixler S, Browning B, Ehrenfels BN, Lucci J, et al. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses 1997; 13 (11):933-943.
17. Zhang XQ, Sorensen M, Fung M, Schooley RT. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob Agents Che-mother 2006; 50 (6):2231-2233.
18. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004; 189 (2):286-291.
19. Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 2009; 53 (2):450-457.
20. Klibanov OM. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr Opin Investig Drugs 2009; 10 (2):190-200.
21. Toma J, Weinheimer SP, Stawiski E, Whitcomb JM, Lewis ST, Petropoulos CJ, et al. Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. J Virol 2011; 85 (8):3872-3880.
22. National Institutes of Health. Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers (TMB-108). http://www.clinicaltrials.gov/ct2/show/NCT01292174. [Accessed March 10, 2013].
23. Pace CS, Fordyce MW, Franco D, Kao CY, Seaman MS, Ho DD. Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J Acquir Immune Defic Syndr 2013; 62 (1):1-9.
24. Suresh P, Wanchu A. Chemokines and chemokine receptors in HIV infection: Role in pathogenesis and therapeutics. J Postgrad Med 2006; 52 (3):210-217.
25. Chatterjee A, Rathore A, Vidyant S, Kakkar K, Dhole TN. Chemokines and chemokine receptors in susceptibility to HIV-1 infection and progression to AIDS. Dis Markers 2012; 32 (3):143-151.
26. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192 (3):466-474.
27. Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whit-comb J, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191 (6):866-872.
28. Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 2008; 46 (10):1617-1623.
29. Nichols WG, Steel HM, Bonny T, Adkison K, Curtis L, Millard J, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 2008 Mar; 52 (3):858-865.
30. Crabb C. GlaxoSmithKline ends aplaviroc trials. AIDS 2006; 20 (5):641.
31. Ryan CT. Trials of aplaviroc halted in treatment-naive patients. AIDS Clin Care 2005; 17 (11): 107-108.
32. Kitrinos KM, Amrine-Madsen H, Irlbeck DM, Word JM, Demarest JF. Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: Detection of aplaviroc resistance requires clonal analysis of envelope. Antimicrob Agents Chemother 2009; 53 (3):1124-1131.
33. Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 196 (2):304-312.
34. Landovitz RJ, Angel JB, Hoffmann C, Horst H, Opravil M, Long J, et al. Phase II study of vicriviroc versus efavirenz (both with zi-dovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis 2008 Oct 15; 198 (8):1113-1122.
35. Schurmann D, Fatkenheuer G, Reynes J, Michelet C, Raffi F, van Lier J, et al. Antiviral activity, pharmacokinetics and safety of vi-criviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007; 21 (10):1293-1299.
36. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49 (11):4721-4732.
37. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359 (14):1442-1455.
38. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359 (14):1429-1441.
39. Hardy WD, Gulick RM, Mayer H, Fatkenheuer G, Nelson M, Heera J, et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010; 55 (5):558-564.
40. Araujo LA, Junqueira DM, de Medeiros RM, Matte MC, Almeida SE. Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC. J Clin Virol 2012; 54 (1):6-10.
41. Ratcliff AN, Shi W, Arts EJ. HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120. J Virol 2013; 87 (2):923-934.
42. Willig JH, Wilkins SA, Tamhane A, Nevin CR, Mugavero MJ, Raper JL, et al. Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretrovi-ral regimen selection in treatment-experienced patients. AIDS Res Hum Retroviruses 2013; 29 (1):105-111.
43. Cuzin L, Trabelsi S, Delobel P, Barbuat C, Reynes J, Allavena C, et al. Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study. J Acquir Immune Defic Syndr 2012; 61 (5):557-564.
44. Gutierrez C, Diaz L, Vallejo A, Hernandez-Novoa B, Abad M, Madrid N, et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One 2011; 6 (12):e27864.
45. Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A, et al. A pilot trial of adding maraviroc to suppressive antiretro-viral therapy for suboptimal CD4(+) T-cell recovery despite sus tained virologic suppression: ACTG A5256. J Infect Dis 2012; 206 (4):534-542.
46. Neff CP, Ndolo T, Tandon A, Habu Y, Akkina R. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One 2010; 5 (12):e15257.
47. Klibanov OM, Williams SH, Iler CA. Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection. Curr Opin Investig Drugs 2010; 11 (8):940-950.
48. Lalezari J, Gathe J, Brinson C, Thompson M, Cohen C, Dejesus E, et al. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. J Acquir Immune Defic Syndr 2011; 57 (2):118-125.
49. Marier JF, Trinh M, Pheng LH, Palleja SM, Martin DE. Pharma-cokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naive patients. Antimicrob Agents Chemother 2011; 55 (6):2768-2774.
50. Liles WC, Rodger E, Broxmeyer HE, Dehner C, Badel K, Calandra G, et al. Augmented mobilization and collection of CD34+ hema-topoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45 (3):295-300.
51. Melby T, Despirito M, Demasi R, Heilek-Snyder G, Greenberg ML, Graham N. HIV-1 coreceptor use in triple-class treatment-experienced patients: Baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 2006; 194 (2):238-246.
52. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44 (6):1667-1673.
53. Flomenberg N, DiPersio J, Calandra G. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol 2005; 114 (4):198-205.
54. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994; 91 (21):9770-9774.
55. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348 (22):2175-2185.
56. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348 (22):2186-2195.
57. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369 (9568):1169-1178.
58. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. Lancet 2006; 368 (9534):466-475.
59. Lu J, Deeks SG, Hoh R, Beatty G, Kuritzkes BA, Martin JN, et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 2006; 43 (1):60-64.
60. Li L, Ben Y, Yuan S, Jiang S, Xu J, Zhang X. Efficacy, stability, and biosafety of sifuvirtide gel as a microbicide candidate against HIV-1. PLoS One 2012; 7 (5):e37381.
61. Wang RR, Yang LM, Wang YH, Pang W, Tam SC, Tien P, et al. Sifuvirtide, a potent HIV fusion inhibitor peptide. Biochem Bio-phys Res Commun 2009; 382 (3):540-544.
62. He Y, Xiao Y, Song H, Liang Q, Ju D, Chen X, et al. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 2008; 283 (17):11126-11134.
63. Liu Z, Shan M, Li L, Lu L, Meng S, Chen C, et al. In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 2011; 286 (5):3277-3287.
64. Yao X, Chong H, Zhang C, Waltersperger S, Wang M, Cui S, et al. Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide. J Biol Chem 2012; 287 (9):6788-6796.
65. Chong H, Yao X, Qiu Z, Sun J, Zhang M, Waltersperger S, et al. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1. FASEB J 2013; 27 (3):1203-1213.
66. Marchand C, Maddali K, Metifiot M, Pommier Y. HIV-1 IN inhibitors: 2010 Update and perspectives. Curr Top Med Chem 2009; 9 (11):1016-1037.
67. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, et al. Antiretroviral activity, pharma-cokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43 (5):509-515.
68. Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, et al. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55 (1):39-48.
69. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374 (9692):796-806.
70. Rockstroh JK, Dejesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive hiv-1 infected patients: Final five-year results from STARTMRK. J Acquir Immune Defic Syndr 2013; 63 (1):77-85.
71. Rockstroh JK, Dejesus E, Saag MS, Yazdanpanah Y, Lennox JL, Wan H, et al. Long-term safety and efficacy of raltegravir (RAL)-based versus efavirenz (EFV)-based combination therapy in treat-ment-naïve HIV-1-infected patients: final 5-year double-blind results from STARTMRK. Washington, DC: XIX International AIDS conference; 2012.
72. Lazzarin A, Dejesus E, Rockstroh JK, Lennox JL, Saag MS, Wan H. Durable and consistent efficacy of raltegravir (RAL) with teno-fovir (TDF) and emtricitabine (FTC) across demographic and baseline prognostic factors in treatment-naïve patients (pts) from STARTMRK at wk 156. 51st Interscience conference on antimicrobial agents and chemotherapy, Chicago; 2011.
73. Rockstroh JK, Lazzarin A, Zhao J, Rodgers AJ, DiNubile MJ, Nguyen BY. Long-term efficacy of raltegravir or efavirenz combined with TDF/FTC in treatment-naive HIV-1-infected patients: week-192 subgroup analyses from STARTMRK. Belgrade: European AIDS conference; 2011.
74. Eron JJ, Jr., Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: A randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011; 11 (12):907-915.
75. Rizk ML, Hang Y, Luo WL, Su J, Zhao J, Campbell H, et al. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother 2012; 56 (6):3101-3106.
76. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359 (4):355-365.
77. Gatell JM, Katlama C, Grinsztejn B, Eron JJ, Lazzarin A, Vittecoq D, et al. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr 2010; 53 (4):456-463.
78. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359 (4):339-354.
79. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: Week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010; 50 (4):605-612.
80. Scherrer AU, von Wyl V, Fux CA, Opravil M, Bucher HC, Fayet A, et al. Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures. J Acquir Immune Defic Syndr 2010; 53 (4):464-471.
81. Scherrer AU, von Wyl V, Boni J, Yerly S, Klimkait T, Burgisser P, et al. Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2011; 57 (1):24-31.
82. Squires KE, Bekker LG, Eron JJ, Cheng B, Rockstroh JK, Marquez F, et al. Safety, Tolerability, and Efficacy of Raltegravir in a Diverse Cohort of HIV-Infected Patients: 48-Week results from the REALMRK Study. AIDS Res Hum Retroviruses 2013; [Epub ahead of print].
83. Harris M, Larsen G, Montaner JS. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologi-cally suppressive regimen. AIDS 2008; 22 (10):1224-1226.
84. De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, et al. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: A randomized open-label trial. Clin Infect Dis 2009; 49 (8):1259-1267.
85. Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, et al. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother 2011; 66 (9):2099-2106.
86. Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, Ito Y, et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem 2006; 49 (5):1506-1508.
87. Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: Results of a Phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 2010; 201 (6):814-822.
88. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramana-than S, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted ata-zanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379 (9835):2429-2438.
89. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramana-than S, et al. Analysis of efficacy by baseline viral load: Phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) versus ritonavir-boosted atazanavir plus mtricit-abine/tenofovir DF in treatment-naive HIV-1-positive subjects: Week 48 results. Washington, DC: XIX International AIDS conference; 2012.
90. Katlama C, Murphy R. Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs 2012; 21 (4):523-530.
91. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimi-crob Agents Chemother 2011; 55 (2):813-821.
92. Min S, Carrod A, Curtis L, Stainby C, Brothers C, Yeo J. Safety profile of dolutegravir (DTG, S/GSK1349572), in combination with other antiretrovirals in antiretroviral (ART)-naïve and ART-experienced adults from two Phase IIb studies. Rome: XIII International AIDS conference; 2011.
93. Erron JE, Durant J, Poizot Martin I, Reynes J, Soriano V, Kumar PN. Activity of a next generation integrase inhibitor (INI), S/GSK1349572, in subjects with HIV exhibiting raltegravir resistance: initial results of VIKING study (ING112961). Vienna: XVII International AIDS conference; 2010.
94. Clotet B, DeJesus E, Lazzarin A, Livroset JM, Moriat P. HIV inte-grase genotypic and phenotypic changes between day 1 and day 11 in subjects with raltegravir (RAL) resistant HIV treated with S/GSK1349572: results of VIKING study (ING112961). Vienna: XVII International AIDS conference; 2010.
95. Erron JE, Kumar PN, Lazzarin A, Richmont G, Soriano V, Huang J. DTG in subjects with HIV exhibiting RAL resistance: Functional monotherapy results of VIKING study cohort II. 18th Conference on retroviruses and opportunistic infections, Boston; 2011.
96. van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: Planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12 (2):111-118.
97. Stellbrink H, Reynes J, Lazzarin A, Voronin E, Pulido F, Felisarta F. Dolutegravir in combination therapy exhibits rapid and sustained antiviral response in ARV-naive adults: 96-Week results from SPRING-1. 19th Conference on retroviruses and opportunistic infections, Seattle; 2012.
98. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C. Once-daily dolutegravir (DTG; S/GSK1345972) is noninferior to raltegravir (RAL) in antiretroviral-naive adults: 48 week results from SPRING-2 (ING113086). Washington, DC: XIX International AIDS conference; 2012.
99. Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG, Fuji-wara T. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr 2012; 61 (3):297-301.
100. Yoshinaga T, M K-K, Seki T, Ishida K, Akihisa E, Kobayashi M. Strong inhibition of wild-type and integrase inhibitor (INI)-resistant HIV integrase (IN) strand transfer reaction by the novel INI S/GSK1349572. Dubrovnik: International HIV and hepatitis virus drug resistance workshop; 2010.
101. Seki T, Wakasa-Morimoto C, Yoshinaga T, Sato A, Fujiwara T, Underwood M. S/GSK1349572 is a potent next generation HIV in-tegrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones,17th Conference on retroviruses and opportunistic infections, San Francisco; 2010.
102. Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and in-tegrase inhibitor-resistant HIV-1 integrase-DNA complexes. An-timicrob Agents Chemother 2011; 55 (10):4552-4559.
103. Min S, DeJesus E, McCurrdy L, Stainby C, Brothers C, Yeo J. Pharmacokinetics (PK) and safety in healthy and HIV-infected subjects and short-term antiviral efficacy of S/GSK1265744, a next generation once daily HIV integrase inhibitor. 49th Interscience conference on antimicrobial agents and chemotherapy (ICAAC), San Francisco; 2009.
104. Underwood M, St Clair M, Johns B, Sato A, Fujiwara T, Spreen W. S/GSK1265744: a next generation integrase inhibitor (INI) with activity against raltegravir-resistant clinical isolates. XVIII International AIDS conference, Vienna; 2010.
105. Dobard CW, Briones MS, Chow SA. Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription. J Virol 2007; 81 (18):10037-10046.
106. Wilkinson TA, Januszyk K, Phillips ML, Tekeste SS, Zhang M, Miller JT, et al. Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase. J Biol Chem 2009; 284 (12):7931-7939.
107. Wu X, Liu H, Xiao H, Conway JA, Hehl E, Kalpana GV, et al. Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleo-protein reverse transcription complex. J Virol 1999; 73 (3):2126-2135.
108. Zhu K, Dobard C, Chow SA. Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J Virol 2004; 78 (10):5045-5055.
109. Di Santo R. Diketo acids derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse tran-scriptase RNase H domain. Curr Med Chem 2011; 18 (22): 3335-3342.
110. Christ F, Shaw S, Demeulemeester J, Desimmie BA, Marchand A, Butler S, et al. Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization. Antimicrob Agents Chemother 2012; 56 (8): 4365-4374.
111. De Luca L, Ferro S, Morreale F, Chimirri A. Inhibition of the interaction between HIV-1 integrase and its cofactor LEDGF/p75: A promising approach in anti-retroviral therapy. Mini Rev Med Chem 2011; 11 (8): 714-727.
112. Meehan AM, Saenz DT, Morrison J, Hu C, Peretz M, Poeschla EM. LEDGF dominant interference proteins demonstrate prenu-clear exposure of HIV-1 integrase and synergize with LEDGF depletion to destroy viral infectivity. J Virol 2011; 85 (7):3570-3583.
113. Christ F, Pickford C, Demeulemeester J, Shaw S, Desimmie BA, Smith-Burchnell C. Pre-clinical evaluation of HIV replication inhibitors that target the HIV-integrase-LEDGF/p75 interaction. Washington, DC: XIX International AIDS conference; 2012.
114. Fenwick C, Bethell R, Cordingley M, Edwards P, Quinson AM, Robinson P. BI 224436, a non-catalytic site integrase inhibitor, is a potent inhibitor of the replication of treatmentnaive and raltegravir-resistant clinical isolates of HIV-1. 51st Interscience conference on antimicrobial agents and chemotherapy, Chicago; 2011.
115. st Interscience conference on antimicrobial agents and chemotherapy, Chicago; 2011.
116. Ueda, Y.C.T.P., Kadow, J. F., Meanwell, N. A., Wang, T., Chen, H., Yeung, K., Zhang, Z., David, K., Pack, S.K., Soundararajan, N., Sirard, P., Kathia., Thoraval, D. Prodrugs of piperazine and substituted piperidine antiviral agents. US8168615 (2012).
117. Dwyer, John., Bray, B. L., Schneider, S. E., Zhang, H., Tvermoes, N.A., Johnston, B.E., Friedrich, P.E. HIV fusion inhibitor peptides with improved biological properties. US8034899 (2011).
118. Lee, E., Melville, C.R., Rotstein, D.M. Heterocyclic antiviral compounds. US7714018 (2010).
119. Regueiro-Ren, A., Swidorski, J., Liu, Z., Wang, T., Zhang, Z., Hamann, L.G., Meanwell, N.A., Carini, D. J., Li, W. Dike-topiperidine derivatives as HIV attachment inhibitors. US8242124 (2012).
120. Olson, W.C., Maddon, P.J. Methods of inhibiting human immunodeficiency virus infection through the administration of synergis-tic combinations of anti-CCR5 monoclonal antibodies, fusion inhibitors, and CD4-GP120 binding inhibitors. US7736649 (2010).
121. Debnath, A.K., Zhang, H., Curreli, F., Antiviral cell-penetrating peptides. US8324153 (2012).
122. Shim, H., Liotta, D.C., Snyder J.P., Zhan, W., Liang, Z. CXCR4 antagonists for the treatment of HIV infection. US8008312 (2011).
123. Jiang, S., Pan, C., Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors. US7919101 (2011).
124. Hamer, D. Commensal strain of E. coli encoding an HIV GP41 protein. US8349586 (2013).
125. Erickson, J.W., Bridon, D.P., Robitaille, M., Krafft G. A., Xie, D., Afonina, E., Liang, J., DeMeyer, S. Long lasting fusion peptide inhibitors for HIV infection. US7741453 (2010).
126. Tsantrizos, Y.S., Bailey, M.D., Bilodeau, F., Carson, R.J., Fader, L., Halmos, T., Kawai, S., Landry, S.R., Laplantea, S., Simoneau, B. Inhibitors of human immunodeficiency virus replication. US8377960 (2013).
127. Naidu, B.N., Peese, K., Dicker, I.B., Li, C., Patel, M., Meanwell, N.A., Walker, M.A. HIV integrase inhibitors. US8383639 (2013).
128. S.L. 4-Oxoquinoline derivatives. US7994194 (2011).
129. Nair, V., Seo, B. I., Uchil, V. R. Pyridinone diketo acids: inhibitors of HIV replication. US7888375 (2011).